Kerry account plan
Global leader food solutions
At a glance
Kerry Group is an Irish B2B taste and nutrition ingredients company for food, beverage and pharma: €6,758m FY2025 revenue, 19,000+ employees.
Kerry Group is a B2B taste and nutrition ingredients company that co-creates products with food, beverage and pharma customers in retail and foodservice, using taste technologies (natural extracts, Tastesense™ salt and sugar reduction, flavours) and biotechnology (fermentation, enzymes, probiotics, proteins). Since selling Kerry Dairy Ireland at the end of 2024 it describes itself as a pure-play taste and nutrition company, sizing its addressable market at c. €85bn. FY2025 revenue from continuing operations was €6,758m (-2.5% reported, volume +3.0%), EBITDA €1,208m at a 17.9% margin, and free cash flow €643m. It has 19,000+ employees and 119 manufacturing facilities in 34 countries. Edmond Scanlon has been CEO since October 2017.
Business units
Americas
€3,674m FY2025 revenueThe largest region, with FY2025 volume growth of 3.8% led by Snacks, Dairy and Bakery and strong growth in foodservice with quick service and fast casual restaurants; revenues in the USA alone were €2,840.0m. In H1 2026 revenue was €1,818m at an 18.9% EBITDA margin, and nine-month 2026 volume grew 4.0%, with LATAM led by Mexico.
APMEA
€1,644m FY2025 revenueAsia Pacific, Middle East and Africa: FY2025 volume grew 4.2%, led by Southeast Asia, Bakery, Meat and Meals, while China was challenged. Kerry opened its first plant in Egypt and a facility in Rwanda; H1 2026 revenue was €831m at a 15.8% margin and nine-month volume grew 5.2% with China returning to growth.
Europe
€1,440m FY2025 revenueVolume fell 0.5% in FY2025 on subdued retail markets, while Beverage and Snacks did well and EBITDA margin expanded 90bps. H1 2026 revenue was €687m at a 16.0% margin; nine-month volume grew 0.7%, led by low / no alcohol beverages, snacks and dairy.
Strategic priorities
- 2030 financial targets
- Announced in July 2026: volume growth of 3-5% on average over 2027-2030 assuming flat end markets, EBITDA margin of 20-21% by 2030, HSD+ constant currency EPS growth, 85%+ cash conversion and 12-13% ROACE by 2030.
- Accelerate 2.0 efficiency programme
- Runs until 2028, covering footprint optimisation in North America and Europe and digital excellence in manufacturing, commercial enablement and global business service centres; it is the primary driver of margin expansion in FY 2026 and FY 2027.
- Renovation, foodservice and emerging markets
- Renovation is around 40% of the pipeline and more than half in North America; foodservice volume grew 5.0% and emerging markets 4.9% in the first nine months of 2026.
- Biotechnology innovation
- Kerry is accelerating biotechnology R&D in next-generation modulation, biotransformation to replace additives and natural preservation; R&D spend is set to rise from 4%-5% to 5%-6% of revenue.
- Digital and AI at scale
- After piloting, Kerry is scaling digital and AI initiatives across commercial, R&D, supply chain, manufacturing and business functions.
Latest results
In H1 2026 revenue was €3,336.4m, down 3.7% reported, with volume growth of 3.3%, pricing of -1.0% from input cost deflation and adverse translation currency of 4.8% from the weaker US$. EBITDA was €558.1m at a 16.7% margin (+60bps) and adjusted EPS rose 7.9% in constant currency to 214.1c. The Q3 2026 statement reported nine-month volume growth of 3.6%, stepping up to 4.1% in Q3, with pricing turning positive (+0.2%) and EBITDA margin up 50bps year to date. Kerry maintains FY2026 guidance of 6% to 10% constant currency adjusted EPS growth.
Investments and deals
- Capacity and innovation centres
- €301m of capex in 2025, including a Biotechnology Centre in Leipzig, enzyme capacity in Cork, coffee extraction in Pennsylvania and customer innovation centres in Dubai, South Jakarta and Frankfurt; 2026 investments include beverage taste capacity in North America, savoury taste in Mexico, proactive health in Spain and a taste footprint in Türkiye.
- Bolt-on M&A
- Bolt-ons of EUR 100 million-EUR 200 million per year in emerging markets and biotechnology (biotics and bioactives, enzymes, food protection and preservation).
- Share buybacks
- €500m of shares repurchased in 2025 and €172.9 million in H1 2026, with a further buyback of up to €300 million planned after the current programme.
Challenges and risks
- Currency translation
- The weaker US$ cut reported revenue by 4.8% in H1 2026 and is a 1-2% headwind to FY2026 EPS.
- Weak European markets
- Europe volumes fell 0.5% in FY2025, with Meals and Bakery still challenged in 2026.
- Input cost inflation
- The CFO expects 2027 to be inflationary, with dairy-based ingredients, some spices and natural oils rising, after deflation in H1 2026.
- Geopolitical and macro uncertainty
- Principal risks include trade wars, tariffs, currency volatility and consumer affordability challenges; China volumes were challenged in 2025.
What leadership says
“We see this as a structural market shift, it's primarily driven by actually increased consumer expectations.”
“We are accelerating our investment in biotechnology innovation and very much doubling down”
“Having piloted and proven several initiatives across the organization, we are now scaling across commercial, R&D, supply chain, manufacturing, and business functions.”
“we currently expect 2027 to be an inflationary year”
Where a supplier can help
- Digital and AI rollout
- Tied to the digital and AI priority and Accelerate 2.0's digital excellence workstream: Kerry is scaling AI across commercial, R&D, supply chain and manufacturing.
- Footprint optimisation
- Tied to Accelerate 2.0: plant consolidation in North America and Europe creates demand for automation, engineering and transition services.
- Biotech R&D tooling
- Tied to the biotechnology innovation priority and the rise of R&D spend to 5%-6% of revenue: lab equipment, fermentation and data tools.
- Procurement and cost management
- Tied to the input cost inflation challenge: sourcing analytics and hedging support for dairy, spices and natural oils.
- Emerging-market expansion
- Tied to new facilities in Egypt, Rwanda, Türkiye and the Middle East: construction, logistics and local distribution partners.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Kerry?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Kerry Group Annual Report 2025
- Kerry Group is a B2B taste and nutrition ingredients company, now described as a "pure-play taste and nutrition company" after selling Kerry Dairy Ireland (31 December 2024); it serves food, beverage and pharma customers across retail and foodservice, an addressable market of c. €85bn.
- FY2025 (continuing operations): revenue €6,758m (2024: €6,929m, -2.5% reported) with volume growth of 3.0%, pricing -0.3%, translation currency -3.9% and disposals net of acquisitions -1.4%.
- EBITDA €1,208m, margin 17.9% (+80bps), driven by the Accelerate programmes, portfolio developments, operating leverage and mix; constant currency adjusted EPS 481.5c (+7.5%); basic EPS 400.2c (-5.7%).
- Three reportable regions from 1 January 2025: Americas €3,674m revenue (volume +3.8%), APMEA €1,644m (+4.2%), Europe €1,440m (-0.5%); foodservice volume +4.6% and emerging markets volume +5.3%.
- Scale: 19,000+ employees, 119 manufacturing facilities in 34 countries, 60+ technology and innovation centres, 1,200+ R&D scientists and €314m R&D spend.
- Accelerate Operational Excellence completed in 2025; Accelerate 2.0 (footprint optimisation and digital excellence) runs until 2028 and underpins the 19-20% EBITDA margin target by 2028.
- Capital allocation: €301m capex, €215m dividends, €500m of share buybacks in 2025; total dividend 140.0c (+10.1%); free cash flow €643m (81% conversion); net debt €2,244m (1.9x EBITDA).
- Leadership changes: Chair Tom Moran retires at the 2026 AGM with Fiona Dawson taking over; Gerry Behan (President & CEO Kerry Taste & Nutrition) retired 31 December 2025; CEO Edmond Scanlon and CFO Marguerite Larkin continue.
- Kerry Group Half Year Results 2026 (Interim Management Report)
- H1 2026 (published 29 July 2026): revenue €3,336.4m (-3.7% reported) with volume growth of 3.3% (Q2: +3.5%), pricing -1.0% reflecting input cost deflation and adverse translation currency of 4.8% from the weaker US$.
- EBITDA €558.1m, margin 16.7% (+60bps), primarily driven by Accelerate 2.0; adjusted EPS 214.1c, +7.9% in constant currency and +2.3% reported.
- Americas: revenue €1,818m, volume +3.7%, margin 18.9%; Europe: €687m, +0.5%, 16.0%; APMEA: €831m, +4.9%, 15.8%.
- Foodservice volume +4.8% and emerging markets +5.0%; growth led by Snacks, Meat, Dairy and Beverage.
- New 2030 targets: volume growth 3-5% (assuming flat end markets), EBITDA margin 20-21% by 2030, HSD+ constant currency EPS growth, 85%+ cash conversion and 12-13% ROACE by 2030.
- Free cash flow €262.3m (76% conversion); net debt €2,369.8m (2.0x EBITDA); interim dividend 46.2c (+10.0%); €172.9m of shares bought back.
- FY2026 guidance of 6% to 10% constant currency adjusted EPS growth maintained; FX translation a 1-2% EPS headwind.
- Kerry Group Q3 Interim Management Statement 2026
- Q3 2026 interim management statement (22 October 2026): year-to-date volume growth of 3.6%, stepping up to 4.1% in Q3, "well ahead of end market growth".
- Pricing -0.6% year to date but +0.2% in Q3, with deflation in H1 turning to inflation; reported revenue down 0.6% year to date after -2.5% translation currency.
- EBITDA margin expanded 50bps, primarily from Accelerate 2.0, while reflecting increased investment in R&D.
- Regions year to date: Americas volume +4.0% (Q3: +4.6%, LATAM led by Mexico), Europe +0.7% (Q3: +1.3%), APMEA +5.2% (Q3: +5.7%).
- Foodservice volume +5.0%; emerging markets +4.9%; Pharma & Other led by excipients.
- Net debt €2.4 billion; intention to launch a further share buyback of up to €300 million after the current programme.
- FY2026 constant currency adjusted EPS growth guidance of 6% to 10% maintained; translation currency ~1% EPS headwind.
- Kerry Group H1 2026 Results and 2030 Targets Q&A Call (transcript)
- H1 2026 results and 2030 targets Q&A call (29 July 2026) with CEO Edmond Scanlon and CFO Marguerite Larkin.
- Scanlon raised the FY2026 volume expectation to close to 3.5% (from 3%), with H2 like Q2, while keeping 6%-10% constant currency EPS guidance.
- 2030 volume target of 3%-5% by region: Americas 3%-5%, Europe around 1%-2%, APMEA 5%-9%; growth drivers are foodservice (mid-single-digit plus), emerging markets and renovation.
- Renovation is around 40% of the pipeline, about 60% in North America; Scanlon calls it "a structural market shift" and front-of-pack labelling in the US "a matter of when, not if".
- Kerry says its foodservice market share is "only still at the low teens"; foodservice business grown by 70% since 2017.
- Larkin: margin target of 20%-21% by 2030 from efficiencies (Accelerate) first, then leverage and mix; R&D spend to rise from 4%-5% to 5%-6%; capex stays 4%-5%; cash conversion target raised to 85% plus.
- M&A: bolt-ons of EUR 100 million-EUR 200 million per year in emerging markets and biotechnology (biotics and bioactives, enzymes, food protection and preservation).
- Kerry Group Q3 2026 Results Call (transcript)
- Q3 2026 results call (22 October 2026) with CEO Edmond Scanlon and CFO Marguerite Larkin.
- Q3 volume growth of 4.1% (nine months 3.6%); Scanlon expects Q4 "similar to Q3" and sees no notable change in consumer demand.
- Margin: 200 basis points of expansion over the past two years and a further 50 basis points expected in 2026; Larkin says Accelerate 2.0 footprint optimisation is "a little bit ahead of plan" and 2027 will be "another year of good margin expansion".
- Kerry is "doubling down" on biotechnology R&D: next-generation modulation, biotransformation to replace additives, natural preservation.
- Investor Day in Beloit, Wisconsin: five next-generation innovation areas each with a potential opportunity "over EUR 50 million"; digital and AI now scaling across commercial, R&D, supply chain and manufacturing.
- Renovation: "more than half the pipeline in North America"; around 80% of the North American snack category still has salt above WHO guidelines; meals reformulation is a 2027+ opportunity.
- Larkin expects 2027 to be inflationary (dairy-based ingredients, spices, natural oils); new buyback of up to EUR 300 million; bolt-on M&A remains active.
Questions about Kerry
What does Kerry Group do?
Kerry Group provides taste and nutrition ingredient solutions to food, beverage and pharma companies, co-creating products with customers in retail and foodservice.
What is Kerry Group's revenue?
FY2025 revenue from continuing operations was €6,758m with EBITDA of €1,208m. H1 2026 revenue was €3,336.4m.
How many employees does Kerry Group have?
19,000+ employees in 185+ locations and 50+ countries, with 119 manufacturing facilities in 34 countries.
Who leads Kerry Group?
Edmond Scanlon is CEO and Marguerite Larkin is CFO; the annual report names Fiona Dawson to take over from Tom Moran as Board Chair at the 2026 AGM.
What are Kerry Group's 2030 targets?
Volume growth of 3-5% a year, an EBITDA margin of 20-21% by 2030, HSD+ constant currency EPS growth, 85%+ cash conversion and 12-13% ROACE.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)